World’s first lung cancer vaccine begins human trials
A 67-year-old patient at the University College London Hospital is the first to receive the first-ever lung cancer vaccine. German biotech firm BioNTech developed this mRNA-based inoculation called BNT116. The vaccine works by activating the immune system so that it recognizes and combats cancer cells. READ: AMICA maps human immune system with AI The researchers
Disclaimer : We make no assurance about the completeness and accuracy of the content of this website. All news on this website is collected from various sources hence information may or may not be true. Money Nations does not verify the reliability of the content published. We do not accept any accountability for loss or damage occurred as a result of reliability on the content of this website.